Brii Biosciences Ownership
BRIBF Stock | USD 0.13 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Brii |
Brii Pink Sheet Ownership Analysis
About 53.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Brii Biosciences recorded a loss per share of 1.42. The entity had not issued any dividends in recent years. Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company was incorporated in 2017 and is based in Beijing, China. Brii Bioscience is traded on OTC Exchange in the United States.The quote for Brii Biosciences Limited is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Brii Biosciences Limited go to https://www.briibio.com.Currently Active Assets on Macroaxis
Other Information on Investing in Brii Pink Sheet
Brii Biosciences financial ratios help investors to determine whether Brii Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Brii with respect to the benefits of owning Brii Biosciences security.